Prab: CSV import

2025-02-20T01:21:46Z

CSV import

← Older revision		Revision as of 01:21, 20 February 2025
Line 32:		Line 32:
	[[Category:Antidiabetic drugs]]		[[Category:Antidiabetic drugs]]
	[[Category:Type 2 diabetes treatments]]		[[Category:Type 2 diabetes treatments]]
			<gallery>
			File:Imeglimin.svg\|Imeglimin
			</gallery>

Prab: CSV import

2025-02-13T03:54:05Z

CSV import

← Older revision		Revision as of 03:54, 13 February 2025
Line 1:		Line 1:
	~~'''~~Imeglimin''' is an experimental drug candidate for the treatment of [[Type 2 diabetes]]. It is being developed by [[Poxel]] and [[Sumitomo Dainippon Pharma]]. Imeglimin works by targeting the [[mitochondria]] to enhance glucose-stimulated insulin secretion and insulin sensitivity, and to preserve beta cell mass and function.		{{Short description\|An oral antidiabetic medication}}
			{{Drugbox
			\| verifiedfields = changed
			\| verifiedrevid = 477002123
			\| image = Imeglimin.svg
			\| image2 =
			}}

	~~== Mechanism of action ==~~		'''Imeglimin''' is an oral antidiabetic medication used in the management of [[type 2 diabetes mellitus]]. It belongs to a novel class of oral hypoglycemic agents known as the ''glimins''. Imeglimin is unique in its mechanism of action, targeting mitochondrial bioenergetics to improve insulin sensitivity and reduce hepatic glucose production.
	Imeglimin'~~s mechanism of action~~ is ~~unique and it acts on three main target organs involved~~ in ~~glucose regulation:~~ the ~~liver, muscle, and the pancreas~~. It ~~is the first clinical candidate in~~ a ~~new~~ class of oral ~~anti-diabetic~~ agents, the ~~[[Glimins]]~~. Imeglimin ~~acts on the mitochondria and specifically improves~~ bioenergetics~~. It enhances glucose-stimulated insulin secretion and~~ insulin sensitivity, and ~~it preserves beta cell mass and function, which allows for sustained~~ glucose ~~lowering effects~~.

	== ~~Clinical trials~~ ==		==Mechanism of Action==
	Imeglimin ~~has completed Phase 1 and Phase 2 development in over 1~~,~~200 subjects~~ in the ~~U.S~~., EU and ~~Japan~~. In the U.S. and EU, Imeglimin has successfully completed Phase 2 development in over 850 patients. In Japan, Imeglimin has completed a Phase 2b clinical trial in 299 treatment-naïve patients and a Phase 3 program is currently ongoing.		Imeglimin acts by modulating mitochondrial function, which is crucial in the pathophysiology of [[type 2 diabetes]]. It enhances insulin sensitivity in muscle tissue, reduces hepatic glucose output, and improves pancreatic beta-cell function. This multifaceted approach helps in maintaining blood glucose levels within the normal range.

	== ~~References~~ ==		==Pharmacokinetics==
	~~<references />~~		Imeglimin is administered orally and is absorbed in the gastrointestinal tract. It undergoes minimal metabolism and is primarily excreted unchanged in the urine. The pharmacokinetic profile of imeglimin supports its use as a twice-daily medication, providing sustained glucose control throughout the day.

	== ~~See also~~ ==		==Clinical Use==
	* [[Type 2 diabetes]]		Imeglimin is indicated for the treatment of type 2 diabetes, particularly in patients who have not achieved adequate glycemic control with other oral antidiabetic agents. It can be used as monotherapy or in combination with other medications such as [[metformin]], [[sulfonylureas]], or [[DPP-4 inhibitors]].
	* [[Poxel]]
	* [[~~Sumitomo Dainippon Pharma~~]]
	* [[~~Mitochondria~~]]
	* [[~~Glimins~~]]

	~~[[Category:Experimental drugs]]~~		==Side Effects==
	~~[[Category:Diabetes]]~~		Common side effects of imeglimin include gastrointestinal disturbances such as nausea and diarrhea. These side effects are generally mild and tend to resolve with continued use. Imeglimin is well-tolerated, with a safety profile similar to other oral antidiabetic agents.

	~~{{stub}}~~		==Development and Approval==
			Imeglimin was developed by Poxel, a pharmaceutical company specializing in metabolic disorders. It has undergone extensive clinical trials to evaluate its efficacy and safety in patients with type 2 diabetes. Imeglimin has been approved for use in several countries and is undergoing further evaluation for approval in additional markets.

			==Related pages==
			* [[Type 2 diabetes mellitus]]
			* [[Insulin resistance]]
			* [[Oral hypoglycemic agents]]
			* [[Mitochondrial function]]

			[[Category:Antidiabetic drugs]]
			[[Category:Type 2 diabetes treatments]]

Prab: CSV import

2024-02-25T21:58:31Z

CSV import

New page

'''Imeglimin''' is an experimental drug candidate for the treatment of [[Type 2 diabetes]]. It is being developed by [[Poxel]] and [[Sumitomo Dainippon Pharma]]. Imeglimin works by targeting the [[mitochondria]] to enhance glucose-stimulated insulin secretion and insulin sensitivity, and to preserve beta cell mass and function.

== Mechanism of action ==
Imeglimin's mechanism of action is unique and it acts on three main target organs involved in glucose regulation: the liver, muscle, and the pancreas. It is the first clinical candidate in a new class of oral anti-diabetic agents, the [[Glimins]]. Imeglimin acts on the mitochondria and specifically improves bioenergetics. It enhances glucose-stimulated insulin secretion and insulin sensitivity, and it preserves beta cell mass and function, which allows for sustained glucose lowering effects.

== Clinical trials ==
Imeglimin has completed Phase 1 and Phase 2 development in over 1,200 subjects in the U.S., EU and Japan. In the U.S. and EU, Imeglimin has successfully completed Phase 2 development in over 850 patients. In Japan, Imeglimin has completed a Phase 2b clinical trial in 299 treatment-naïve patients and a Phase 3 program is currently ongoing.

== References ==
<references />

== See also ==
* [[Type 2 diabetes]]
* [[Poxel]]
* [[Sumitomo Dainippon Pharma]]
* [[Mitochondria]]
* [[Glimins]]

[[Category:Experimental drugs]]
[[Category:Diabetes]]

{{stub}}

Imeglimin - Revision history

Prab: CSV import

Prab: CSV import

Prab: CSV import